Gurugram-based dialysis care provider VitusCare has raised $3 million, or nearly Rs 30 crore, in a Series B funding round. The round saw participation from Singapore-based healthcare growth equity firm Liberty Ridge Capital, HDFC Bank, Equentis and NAFA Capital Advisors.
Existing investors 1Crowd and 3i Partners also participated, along with several angel investors, the startup said. VitusCare plans to use the fresh capital to expand its dialysis centre network, strengthen its technology, train healthcare staff and explore markets outside India.
The latest funding takes the company total capital raised to around $8 million. The round comes about two and a half years after VitusCare raised $2.7 million in a Series A round in April 2024, led by Tomorrow Capital. The earlier round also included 1Crowd, 3i Partners and angel investors. The company had raised Rs 10.83 crore in a seed round in 2019.
Increasing Dialysis Network
VitusCare said its revenue has nearly tripled since its previous funding round in 2024. During the same period, its network expanded from 22 to more than 60 dialysis centres across nine states and over 50 cities. Its workforce also increased from 110 to 300 employees.
The company has treated more than 35,000 patients and conducted over eight lakh dialysis sessions so far. It reported positive corporate EBITDA in FY26, attributing the performance to faster break-even at newly opened centres and same-centre growth of more than 30%.
VitusCare aims to increase its network to more than 100 centres by the end of FY27. Reaching this target would require it to add around 40 centres in a little over four months. The company is also exploring selected markets in Asia.
Capital-Light Model
Unlike healthcare providers that establish standalone dialysis clinics, VitusCare operates through a capital-light model that it describes as a 'shop-in-shop' arrangement. Under this model, it sets up dialysis units inside existing hospitals instead of building separate facilities.
VitusCare provides dialysis machines, trained technicians, technology and daily operations, while partner hospitals provide the required space and infrastructure. The arrangement allows the company to expand its network without bearing the full cost of setting up and maintaining standalone centres. It is particularly relevant to its expansion plans in Tier II and Tier III cities.
Company is also developing AI-based business modules to improve its operations and care delivery. It plans to establish a Technician Academy to train professionals for dialysis services, an area where skilled staff are required to support network expansion.
Targets Growing Demand
India has a significant need for dialysis services. Government figures estimate that around 2.2 lakh new patients develop end-stage renal disease every year.
Government also runs the Pradhan Mantri National Dialysis Programme, which was launched in 2016 to provide free dialysis services to patients below the poverty line. According to a written reply by Minister of State for Health Prataprao Jadhav in the Lok Sabha, the programme had 1,704 operational centres across 751 districts as of June 30, 2025.
VitusCare operates in a competitive private dialysis care market. Its competitors include NephroPlus, Apex Kidney Care, DCDC Kidney Care, 7Med and Rahi Care. These providers operate in the kidney care and dialysis services segment, where expansion depends on access to hospital infrastructure, trained technicians, equipment and consistent clinical standards. As VitusCare increases its centre count, maintaining service quality and centre-level performance will remain important to its growth plans.
About VitusCare
Startup was founded in 2017 by Prabhat Shrivastava, Saurabh Pokhariyal and Pankaj Tandon, VitusCare provides dialysis services through units set up inside existing hospitals. Its capital-light business model relies on partner hospitals for space and infrastructure, while the company manages equipment, trained staff, technology and daily operations. Shrivastava is the founder and CEO, while Pokhariyal, a nephrologist, previously served as chief medical director and Tandon held the position of chief financial officer.